Response to press comments
10/10/2008 1:35pm
UK Regulatory
RNS Number : 5965F
Medical Marketing Int'l Group PLC
10 October 2008
Response to press comments
Friday 10 October 2008 - Medical Marketing International Group plc ("MMI" or the "Company") (AIM:MMG), the life sciences company focused
on the development of drugs for cancer, wishes to clarify that, despite press comments, the Company is not aware of any additional results
to be notified in relation to the University of Southampton Phase I/II clinical study in prostate cancer. The most recent study results were
notified by the Company on 4 April 2008.
Enquiries:
Medical Marketing International Group plc
Phil Cartmell, Non-executive Chairman Tel: +44 (0) 1223 477 677
Mark Burton, Chief Technical Officer
Rob Sprawson, Chief Financial Officer
FinnCap
Sam Smith/Charlie Cunningham Tel: +44 (0)20 7600 1658
Financial Dynamics
David Yates/Emma Thompson Tel: +44 (0)20 7831 3113
About MMI
Medical Marketing International Group plc ("MMI") is a life sciences company that identifies, acquires and develops world-class
compounds and technologies for the treatment of cancer. The Company manages the preclinical and early clinical development of drug
candidates before pursuing licensing partners to manage late-stage development. Please visit www.mmigroup.co.uk for further information.
Notwithstanding the inclusion on this release by MMI of a website address and/or another electronic address, MMI does not accept any
notices or any other documents or communication via its website or other electronic address. All such notices, documents or communication
shall be in hard copy format only. Accordingly the provisions of section 333 Companies Act 2006 allowing persons to communicate with MMI
electronically shall not apply to MMI.
-ends-
This information is provided by RNS
The company news service from the London Stock Exchange
END
RSPBDBDGDXBGGIG